Triumvira Immunologics Appoints Life Sciences Industry Leader Robert Williamson as President and Chief Business Officer

2022-10-25

细胞疗法IPO

AUSTIN, Texas & SOUTH SAN FRANCISCO, Calif. & HAMILTON, Ontario--(BUSINESS WIRE)-- Triumvira Immunologics, Inc.Triumvira Immunologics, Inc. (“Triumvira”), a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat patients with cancer, today announced the appointment of Robert Williamson as President and Chief Business Officer. Mr. Williamson will lead business development and strategy for Triumvira Triumvira, and will work within Triumvira’s leadership team to establish new value-creating partnerships, drive long-term strategic plans, and advance fundraising activities. This press release features multimedia. View the full release here: Robert Williamson, President and Chief Business Officer of Triumvira (Photo: Triumvira Triumvira) Mr. Williamson brings more than 25 years of experience in the biotechnology sector, leading company business development and financing efforts through partnerships, private funding and public capital markets. His accomplishments include orchestrating the exits of numerous biotech companies, including guiding the growth, IPO, financing, commercial ramp-up and sale of Pharmasset to Gilead for $11 billion. “We are delighted to welcome Rob to the team and look forward to working together to advance Triumvira’s mission on the heels of our recent clinical accomplishments and as we advance our robust pipeline,” said Paul Lammers, M.D., M.Sc., Chief Executive Officer of Triumvira. “Rob has a long track record of building companies and delivering value for various stakeholders, and he brings tremendous experience and perspective to our leadership team.” Prior to joining Triumvira Triumvira, Mr. Williamson was President and Chief Executive Officer at BioTheryX, Inc. He also held senior leadership roles at PharmAkea, Inc., ATXCo, Arriva Pharmaceuticals, Inc., Eos Biotechnology, Inc., and DoubleTwist, Inc. Throughout his career, Mr. Williamson has served as a board member for a number of companies including Pharmasset, Inc., and Progen Pharmaceuticals. Earlier in his career, he was Partner at The Boston Consulting Group and Research Assistant at the Federal Reserve Board. Mr. Williamson earned a Master of Business Administration from the Stanford University Graduate School of Business and a Bachelor of Arts in Economics from Pomona College. Mr. Williamson commented, “I am thrilled to join the Triumvira team and to work with experienced industry professionals to advance cell therapies that have the potential to transform the treatment of cancer. Triumvira is developing an exciting and innovative approach to harness the power of cell therapies across a vast range of tumor targets, and I look forward to working with the team to make this technology a reality for patients who have limited options today.” About Triumvira Immunologics Triumvira Immunologics Triumvira is a clinical-stage company developing a best-in-class, rationally designed cell therapy platform based on its proprietary T cell Antigen Coupler (TAC) technology. Its lead candidate, TAC01-HER2, is being evaluated in an ongoing Phase 1/2 trial for HER2-positive solid tumors with positive initial safety and efficacy data to-date. Triumvira’s pipeline includes other compelling pre-clinical solid tumor programs targeting Claudin 18.2, GUCY2C and GPC3, among others, with anticipated IND filings over the next few years. Supporting the pipeline has been an industrialized, drug-like, approach to manufacturing, including the first-mover adoption of the Lonza Cocoon® Platform that has yielded high quality product and a very high manufacturing success rate at a lower cost compared to other autologous approaches. Building on the proof-of-concept of its clinical-stage autologous TAC01-HER2 program, Triumvira Triumvira is continuing to develop and advance its gamma delta allogeneic pipeline with IND filings anticipated over the next three years.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。

机构